Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patients

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

ESMO open·2026

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

ESMO open·2025

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

British journal of cancer·2023

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

ESMO open·2022

COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC).

ESMO open·2021

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Biochemical pharmacology·2017

Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Adjuvant chemotherapy with cisplatin and gemcitabine compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Mapping developmental and targeted secretory signatures of euploid and aneuploid human embryos using an advanced endometrial model.

Human reproduction (Oxford, England)·2026

Protective effects of testosterone replacement therapy on brain tumor outcomes: The Mayo Clinic experience.

Neuro-oncology advances·2026

Development and Validation of a Lipid Metabolism-Related Gene Prognostic Model for Breast Cancer: Integrating Risk Score and Nomogram.

Breast care (Basel, Switzerland)·2026

Machine learning-derived intracellular protein-based prognostic model reflecting a senescence-associated secretory phenotype-driven immunosuppressive microenvironment in lung adenocarcinoma.

PeerJ·2026

Multi-method Machine-Learning Identification of IL11 as a Key Gene in Kidney Stone Disease: Mechanistic Clues and Diagnostic Potential.

Cureus·2026

Nirmatrelvir/Ritonavir and Subsequent PCR Negativity in Patients With B-Cell Lymphoma and Prolonged SARS-CoV-2 PCR Positivity: A Case Series.

EJHaem·2026

Related Experiment Videos

Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative

Related Concept Videos

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC).

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.

Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.

Adjuvant chemotherapy with cisplatin and gemcitabine compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).

Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.

A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.

Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW.

Mapping developmental and targeted secretory signatures of euploid and aneuploid human embryos using an advanced endometrial model.

Protective effects of testosterone replacement therapy on brain tumor outcomes: The Mayo Clinic experience.

Development and Validation of a Lipid Metabolism-Related Gene Prognostic Model for Breast Cancer: Integrating Risk Score and Nomogram.

Machine learning-derived intracellular protein-based prognostic model reflecting a senescence-associated secretory phenotype-driven immunosuppressive microenvironment in lung adenocarcinoma.

Multi-method Machine-Learning Identification of IL11 as a Key Gene in Kidney Stone Disease: Mechanistic Clues and Diagnostic Potential.

Nirmatrelvir/Ritonavir and Subsequent PCR Negativity in Patients With B-Cell Lymphoma and Prolonged SARS-CoV-2 PCR Positivity: A Case Series.

Related Experiment Videos

Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative...

Related Concept Videos

Related Articles

Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative